Receive monthly emails about the latest oncology research and technology, new patient services, resources and more!

Please select an option below to help us tailor your newsletter to best suit your content interests!

No thanks
BREAST: Metastatic: ER+, HER2neg, 1st line: BO41843

A Phase III Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of GDC-9545 Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Patients With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer

Title
Roche BO41843 (Breast 1st line ER+)
Study Title

A Phase III Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of GDC-9545 Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Patients With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer

Site Link
Malignancy
Breast cancer
Stage
Disease Setting
Metastatic/Palliative
Line Of Therapy
1st line (pre-chemo)
Investigational Agent
GDC-9545
Drug Class
Selective estrogen receptor degrader (SERD)
PI
Greg Vidal, MD, PhD
Sponsor
Hoffmann-LaRoche
Phase
Status
Key Eligibility Criteria
Key Eligibility Criteria Details
  • Postmenopausal or pre-menopausal but treated with LHRH agonist therapy for the duration of study treatment
  • Locally advanced or metastatic adenocarcinoma of the breast not curable
  • Documented ER-positive and HER2-negative
  • No prior systemic anti-cancer therapy for metastatic disease
  • Measurable disease
  • ECOG PS 0-1
  • No disease recurrence within 12 months of treatment with an AI or a CDK4/6 inhibitor in adjuvant/neoadjuvant setting
  • No prior SERD
  • No active CNS disease
Objective
  • Primary
    • PFS
  • Secondary
    • OS
    • ORR
    • DOR
    • CBR
    • Deterioration in pain level and physical functioning
    • Safety
    • PK
Assessment Frequency
_
Assessment Frequency 2
_



Assessment Frequency Link
Path
ER+ (positive), HER2 - (negative)
Dosing Frequency
Control Agents
AI, palbociclib
Study Protocol
Randomized
Yes
X